Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Tuberculosis, Pulmonary | 9 | 2020 | 1171 | 1.54 | Why? |
| Tuberculosis | 8 | 2021 | 2895 | 0.91 | Why? |
| Sputum | 6 | 2021 | 1720 | 0.90 | Why? |
| Mycobacterium tuberculosis | 7 | 2021 | 1164 | 0.90 | Why? |
| Caliciviridae Infections | 2 | 2016 | 229 | 0.86 | Why? |
| Norovirus | 2 | 2016 | 294 | 0.81 | Why? |
| Gastroenteritis | 3 | 2017 | 489 | 0.78 | Why? |
| Rotavirus Infections | 5 | 2018 | 355 | 0.68 | Why? |
| Acute-Phase Proteins | 1 | 2018 | 177 | 0.67 | Why? |
| Chemokine CXCL10 | 2 | 2018 | 565 | 0.67 | Why? |
| Isoniazid | 1 | 2017 | 105 | 0.66 | Why? |
| Rural Health | 1 | 2019 | 243 | 0.62 | Why? |
| Diarrhea | 5 | 2020 | 2743 | 0.44 | Why? |
| Rotavirus | 4 | 2018 | 329 | 0.39 | Why? |
| Ethiopia | 5 | 2019 | 1222 | 0.38 | Why? |
| Sodium Hypochlorite | 1 | 2007 | 110 | 0.32 | Why? |
| Molecular Diagnostic Techniques | 1 | 2021 | 4239 | 0.28 | Why? |
| Antitubercular Agents | 3 | 2017 | 775 | 0.23 | Why? |
| Tuberculosis, Multidrug-Resistant | 3 | 2021 | 433 | 0.23 | Why? |
| Genotype | 6 | 2018 | 4697 | 0.23 | Why? |
| HIV Infections | 5 | 2017 | 11620 | 0.22 | Why? |
| Molecular Typing | 2 | 2018 | 280 | 0.20 | Why? |
| Plant Structures | 1 | 2018 | 9 | 0.19 | Why? |
| Citrus | 1 | 2018 | 29 | 0.18 | Why? |
| Oils, Volatile | 1 | 2019 | 127 | 0.17 | Why? |
| Nigeria | 4 | 2018 | 2292 | 0.17 | Why? |
| Diabetes Mellitus, Type 2 | 2 | 2018 | 6166 | 0.16 | Why? |
| Blood Specimen Collection | 1 | 2021 | 387 | 0.16 | Why? |
| Phenols | 1 | 2018 | 226 | 0.15 | Why? |
| Diabetes Mellitus, Experimental | 1 | 2018 | 192 | 0.15 | Why? |
| Prevalence | 7 | 2021 | 25773 | 0.15 | Why? |
| Child, Preschool | 10 | 2020 | 36283 | 0.15 | Why? |
| Feces | 3 | 2020 | 4235 | 0.15 | Why? |
| Disclosure | 1 | 2020 | 423 | 0.15 | Why? |
| HIV Seropositivity | 1 | 2017 | 320 | 0.15 | Why? |
| Disease Eradication | 1 | 2021 | 581 | 0.14 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.13 | Why? |
| Acute Disease | 2 | 2021 | 6029 | 0.13 | Why? |
| Anti-Asthmatic Agents | 1 | 2019 | 427 | 0.13 | Why? |
| DNA, Bacterial | 1 | 2018 | 835 | 0.13 | Why? |
| Insulin Resistance | 1 | 2018 | 669 | 0.12 | Why? |
| Molecular Epidemiology | 3 | 2018 | 1638 | 0.11 | Why? |
| Cross-Sectional Studies | 6 | 2019 | 53120 | 0.11 | Why? |
| Yemen | 1 | 2011 | 136 | 0.11 | Why? |
| Cost-Benefit Analysis | 1 | 2021 | 2259 | 0.11 | Why? |
| Brazil | 4 | 2020 | 12582 | 0.11 | Why? |
| Seroconversion | 1 | 2020 | 2515 | 0.10 | Why? |
| Infant | 6 | 2020 | 30274 | 0.10 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.10 | Why? |
| Convalescence | 1 | 2021 | 2829 | 0.10 | Why? |
| Glycated Hemoglobin A | 1 | 2017 | 1316 | 0.09 | Why? |
| Humans | 35 | 2021 | 930598 | 0.09 | Why? |
| Insulin | 1 | 2018 | 1316 | 0.09 | Why? |
| Hospitals, Teaching | 1 | 2017 | 1609 | 0.09 | Why? |
| Community Health Services | 1 | 2017 | 1000 | 0.09 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.09 | Why? |
| Male | 19 | 2021 | 367725 | 0.09 | Why? |
| Adolescent | 9 | 2020 | 86841 | 0.09 | Why? |
| Sequence Analysis, DNA | 1 | 2016 | 2830 | 0.09 | Why? |
| Health Surveys | 1 | 2019 | 2841 | 0.08 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2020 | 13720 | 0.08 | Why? |
| Female | 17 | 2021 | 380317 | 0.08 | Why? |
| Evidence-Based Medicine | 1 | 2020 | 3228 | 0.08 | Why? |
| Plant Extracts | 1 | 2018 | 1514 | 0.08 | Why? |
| Family Characteristics | 1 | 2017 | 2551 | 0.08 | Why? |
| Health Services Needs and Demand | 1 | 2021 | 3419 | 0.08 | Why? |
| Outpatient Clinics, Hospital | 1 | 2011 | 523 | 0.08 | Why? |
| Cytokines | 2 | 2019 | 15010 | 0.07 | Why? |
| Chi-Square Distribution | 1 | 2009 | 961 | 0.07 | Why? |
| Mass Screening | 2 | 2017 | 8005 | 0.07 | Why? |
| Hypoglycemic Agents | 1 | 2018 | 2165 | 0.07 | Why? |
| Age Distribution | 2 | 2020 | 3567 | 0.07 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.07 | Why? |
| Anti-HIV Agents | 1 | 2017 | 2209 | 0.07 | Why? |
| Point-of-Care Systems | 1 | 2018 | 2955 | 0.07 | Why? |
| Saliva | 1 | 2020 | 4679 | 0.07 | Why? |
| Aging | 1 | 2020 | 3581 | 0.07 | Why? |
| Child | 7 | 2020 | 70012 | 0.06 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.06 | Why? |
| Specimen Handling | 1 | 2021 | 6190 | 0.06 | Why? |
| Immunologic Factors | 1 | 2019 | 4206 | 0.06 | Why? |
| Treatment Outcome | 5 | 2017 | 51732 | 0.06 | Why? |
| Adult | 12 | 2021 | 244371 | 0.06 | Why? |
| Contact Tracing | 2 | 2020 | 8448 | 0.05 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.05 | Why? |
| Global Health | 2 | 2021 | 13911 | 0.05 | Why? |
| Immunoglobulin G | 2 | 2020 | 21571 | 0.05 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.05 | Why? |
| Streptozocin | 1 | 2018 | 29 | 0.05 | Why? |
| Receptor, Insulin | 1 | 2018 | 18 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2017 | 5002 | 0.05 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.05 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.05 | Why? |
| Prospective Studies | 2 | 2017 | 43301 | 0.04 | Why? |
| Antibiotics, Antitubercular | 1 | 2017 | 65 | 0.04 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.04 | Why? |
| Dried Blood Spot Testing | 1 | 2021 | 383 | 0.04 | Why? |
| Secondary Metabolism | 1 | 2017 | 61 | 0.04 | Why? |
| Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 7868 | 0.04 | Why? |
| Diet, Western | 1 | 2017 | 42 | 0.04 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.04 | Why? |
| Staining and Labeling | 1 | 2018 | 169 | 0.04 | Why? |
| Glucose Tolerance Test | 1 | 2018 | 238 | 0.04 | Why? |
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 220 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2021 | 10697 | 0.04 | Why? |
| Islets of Langerhans | 1 | 2018 | 138 | 0.04 | Why? |
| Bacterial Typing Techniques | 1 | 2018 | 273 | 0.04 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.04 | Why? |
| Disinfectants | 1 | 2007 | 1077 | 0.04 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.04 | Why? |
| Rats, Wistar | 1 | 2018 | 621 | 0.04 | Why? |
| Pharyngitis | 1 | 2020 | 687 | 0.04 | Why? |
| Middle Aged | 9 | 2021 | 270681 | 0.04 | Why? |
| Rotavirus Vaccines | 1 | 2018 | 203 | 0.04 | Why? |
| Genotyping Techniques | 1 | 2018 | 360 | 0.04 | Why? |
| Hypertension | 1 | 2017 | 8895 | 0.04 | Why? |
| Abdominal Pain | 1 | 2020 | 858 | 0.03 | Why? |
| Lung | 2 | 2020 | 31049 | 0.03 | Why? |
| Chromatography, High Pressure Liquid | 1 | 2018 | 669 | 0.03 | Why? |
| Platelet Count | 1 | 2020 | 1381 | 0.03 | Why? |
| Nose | 1 | 2020 | 1093 | 0.03 | Why? |
| Interleukin-17 | 1 | 2019 | 602 | 0.03 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.03 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.03 | Why? |
| Phylogeography | 1 | 2018 | 824 | 0.03 | Why? |
| Genetic Variation | 2 | 2018 | 3919 | 0.03 | Why? |
| Th17 Cells | 1 | 2019 | 657 | 0.03 | Why? |
| Th2 Cells | 1 | 2017 | 680 | 0.03 | Why? |
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2018 | 624 | 0.03 | Why? |
| Pharynx | 1 | 2020 | 1544 | 0.03 | Why? |
| Adipose Tissue | 1 | 2018 | 612 | 0.03 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.03 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.03 | Why? |
| Phylogeny | 1 | 2011 | 13341 | 0.03 | Why? |
| Gastrointestinal Tract | 1 | 2020 | 1113 | 0.03 | Why? |
| Tandem Mass Spectrometry | 1 | 2018 | 1031 | 0.03 | Why? |
| Cluster Analysis | 1 | 2020 | 3001 | 0.03 | Why? |
| Creatinine | 1 | 2018 | 1443 | 0.03 | Why? |
| Liver Function Tests | 1 | 2018 | 1325 | 0.03 | Why? |
| Risk Factors | 4 | 2020 | 71621 | 0.03 | Why? |
| National Health Programs | 1 | 2018 | 807 | 0.03 | Why? |
| Th1 Cells | 1 | 2017 | 1228 | 0.03 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.03 | Why? |
| Overweight | 1 | 2017 | 916 | 0.03 | Why? |
| Leukocyte Count | 1 | 2020 | 3178 | 0.03 | Why? |
| Phytotherapy | 1 | 2017 | 743 | 0.03 | Why? |
| Risk Reduction Behavior | 1 | 2017 | 946 | 0.02 | Why? |
| Trust | 1 | 2020 | 1487 | 0.02 | Why? |
| Infant, Newborn | 1 | 2020 | 23105 | 0.02 | Why? |
| Program Evaluation | 1 | 2017 | 1929 | 0.02 | Why? |
| Probiotics | 1 | 2017 | 694 | 0.02 | Why? |
| Infectious Disease Medicine | 1 | 2012 | 311 | 0.02 | Why? |
| Social Determinants of Health | 1 | 2021 | 1757 | 0.02 | Why? |
| Early Diagnosis | 1 | 2017 | 2443 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2017 | 2886 | 0.02 | Why? |
| Hypersensitivity | 1 | 2019 | 1137 | 0.02 | Why? |
| Quality Improvement | 1 | 2021 | 2435 | 0.02 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.02 | Why? |
| Civil Defense | 1 | 2020 | 1687 | 0.02 | Why? |
| Immunomodulation | 1 | 2017 | 1472 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2017 | 1414 | 0.02 | Why? |
| Respiratory System | 1 | 2020 | 3213 | 0.02 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.02 | Why? |
| Emergency Service, Hospital | 1 | 2011 | 14232 | 0.02 | Why? |
| Drug Resistance, Microbial | 1 | 2010 | 419 | 0.02 | Why? |
| Sex Distribution | 1 | 2013 | 2083 | 0.02 | Why? |
| Decision Making | 1 | 2020 | 3132 | 0.02 | Why? |
| Forecasting | 1 | 2020 | 4492 | 0.02 | Why? |
| Caliciviridae | 1 | 2004 | 34 | 0.02 | Why? |
| Electrophoresis, Agar Gel | 1 | 2004 | 48 | 0.02 | Why? |
| Animals | 3 | 2019 | 78931 | 0.02 | Why? |
| Aged | 5 | 2020 | 215776 | 0.02 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.02 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.02 | Why? |
| Retrospective Studies | 2 | 2020 | 105322 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Europe | 1 | 2020 | 12702 | 0.02 | Why? |
| Computational Biology | 1 | 2018 | 4514 | 0.01 | Why? |
| Nepal | 1 | 2006 | 1004 | 0.01 | Why? |
| Microscopy, Electron | 1 | 2004 | 830 | 0.01 | Why? |
| Models, Theoretical | 1 | 2020 | 6659 | 0.01 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.01 | Why? |
| Asthma | 1 | 2019 | 4383 | 0.01 | Why? |
| Poverty | 1 | 2012 | 2302 | 0.01 | Why? |
| Anti-Inflammatory Agents | 1 | 2019 | 6153 | 0.01 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.01 | Why? |
| United Kingdom | 1 | 2020 | 18046 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
| Risk | 1 | 2012 | 5288 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| World Health Organization | 1 | 2012 | 4213 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.01 | Why? |
| Pilot Projects | 1 | 2010 | 5182 | 0.01 | Why? |
| Health Promotion | 1 | 2012 | 2020 | 0.01 | Why? |
| Mice | 1 | 2017 | 21357 | 0.01 | Why? |
| Obesity | 1 | 2018 | 7388 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.01 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.01 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Vaccination | 1 | 2018 | 19050 | 0.01 | Why? |
| Iran | 1 | 2004 | 5467 | 0.01 | Why? |
| Health Policy | 1 | 2012 | 6242 | 0.01 | Why? |
| Seasons | 1 | 2004 | 4071 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Antigens, Viral | 1 | 2004 | 6298 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2012 | 29620 | 0.00 | Why? |
| Aged, 80 and over | 1 | 2010 | 88759 | 0.00 | Why? |
Cuevas's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(210)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(148)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_